Reforgene named a potential unicorn enterprise in China for the second consecutive year

On October 24, 2024, the Great Wall Enterprise Strategy Research Institute in Beijing released the "GEI Report on China's Potential Unicorn Enterprises 2024". With its innovative achievements and influence in the field of gene editing innovative medicines, Reforgene was selected as a China potential unicorn enterprise. Since 2023, Reforgene has been listed among China's potential unicorn enterprises twice in a row, fully reflecting the high recognition by authoritative industry research institutions of the company's technological content, industry model and development potential. As outstanding representatives of technological and commercial development, potential unicorn enterprises are expected to continue playing an important role in leading scientific and technological innovation, opening up new fields and shaping new drivers and advantages, and are also typical representatives of new quality productive forces and important indicators of regional innovation vitality.

About Reforgene

Reforgene Medicine is one of China's leading innovative gene editing drug companies, driven by gene editing technology and dedicated to bringing novel medicines to life. Reforgene has a high-caliber team that applied gene editing to explore the treatment of genetic diseases at an early stage internationally, and has accumulated pioneering achievements in hematology, ophthalmology and other disease areas, with strong technical capabilities in gene editing tool innovation, drug development strategy, novel animal model construction, and multi-level efficacy and safety assessment, operating both in vivo and ex vivo drug development. Reforgene's mission is to deliver accessible, curative medicines for patients with serious diseases through innovative genetic technologies. The company currently has pipeline programs across genetic diseases, complex diseases and oncology. Its innovative beta-thalassemia medicine has achieved globally leading clinical progress, it achieved the world's first cure of an alpha-thalassemia patient, and the IND application for its first-in-class Usher syndrome gene editing medicine has been approved by regulators in both China and the United States.